Statera Biopharma Inc. (STAB)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Statera Biopharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 500 | $1,150 | $0.05 | -$1,149.95 | -100% |
Statera Biopharma Inc. (STAB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Statera Biopharma Inc. ever had a stock split?
Statera Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Blake Hawley CEO | NASDAQ (CM) Exchange | 857561104 CUSIP |
| US Country | 46 Employees | - Last Dividend | 28 Jan 2015 Last Split | 25 Jul 2006 IPO Date |
Overview
Statera BioPharma, Inc. is a Fort Collins, Colorado-based clinical-stage biopharmaceutical company committed to the development of novel immunotherapies. These therapies are designed to address a wide spectrum of diseases, including autoimmune diseases, neutropenia/anemia, emerging viruses, and various forms of cancer. Utilizing a proprietary platform, Statera BioPharma aims to rebalance the body's immune system and restore homeostasis. The company’s approach involves activating the body's essential immune defenses by directly eliciting an antigen-specific response from killer T-cells and antibodies in patients. Initially known as Cytocom, Inc., the organization rebranded to Statera BioPharma, Inc. in September 2021. As a subsidiary of Biostax Corp., Statera BioPharma stands at the forefront of immunotherapy innovation, seeking to provide groundbreaking treatments for a range of serious health conditions.
Products and Services
- STAT-201 for Crohn's Disease
This clinical program is focused on developing a treatment for Crohn's disease, a chronic inflammatory bowel disease. Employing Statera BioPharma's immunotherapy platform, STAT-201 aims to directly elicit the production of antigen-specific killer T-cells and antibodies within patients, specifically targeting the immune dysfunctions that contribute to the disease.
- Entolimod for Hematology
Statera BioPharma is advancing Entolimod as a hematological treatment option, particularly aimed at addressing conditions such as neutropenia and anemia. The therapy leverages the company's innovative approach to stimulate the immune system, potentially offering a new path for treating these common yet debilitating blood disorders.
- STAT-401 for Pancreatic Cancer
Targeting one of the most aggressive and hard-to-treat cancers, STAT-401 represents Statera BioPharma's commitment to expanding the application of its immunotherapy platform to oncology. This program focuses on pancreatic cancer, seeking to activate the patient's immune response against tumor cells to inhibit disease progression.
- STAT-205 for COVID-19
Reflecting the company's adaptability and relevance in addressing emergent global health threats, STAT-205 is a clinical program aimed at combating COVID-19. Through the activation of antigen-specific killer T-cells and antibodies, this treatment intends to bolster the immune system's ability to fight off the novel coronavirus effectively.
- Fibromyalgia and Multiple Sclerosis Treatments
In addition to its targeted disease programs, Statera BioPharma is also developing therapies for fibromyalgia and multiple sclerosis. By applying its proprietary immunotherapy technology, the company aspires to provide new hope for patients suffering from these chronic conditions, through the modulation and rebalancing of the immune system.
